Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.84
(
-0.57%
)
Bitcoin
70,074.00
(
0.25%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 80724

Friday, 07/10/2009 7:44:10 AM

Friday, July 10, 2009 7:44:10 AM

Post# of 257262
Re: VRTX Seeks to Monetize Telaprevir EU Milestones from JNJ

Any guess on the risk adjusted discount (aside from the NPV discount)?

My guess: VRTX can get a lump-sum payment of $150-175M, i.e. a 30-40% discount that takes into account both the present-value arithmetic and the risk that the milestones won’t be triggered on time (or at all). What do you think?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now